The combination of RAAS and SGLT2 inhibitors should be advocated as concomitant inhibition appears to achieve better cardiovascular and renal outcomes.40 GLP-1 Receptor Agonists The LEADER, HARMONY OUTCOMES and EXSCEL trials demonstrated the cardiovascular safety of GLP-1 RAs.1315 Meta-analyses have reported favourable cardiovascular safety profiles for GLP-1 RAs, especially in MACE and nonfatal stroke events.16,17,45 Improvements in the composite kidney outcome were also detected.45 However, the benefits were less clear-cut in comparison with SGLT2 inhibitors and somewhat conflicting across trials
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
By supporting brain health, reducing cravings, and promoting overall well-being, NAD+ may help individuals achieve and maintain sobriety
When compared with the sodiumglucose cotransporter 2 (SGLT2) inhibitors group, the GLP-1RAs group showed no evidence of a difference in terms of new-onset heart failure (HR 0.97
Each bottle comes with 100 tablets/servings, all containing 1000mg of L-Carnitine
In this episode of Modern Thyroid and Wellness, McCall sits down with Dr